Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $45.6000 (-1.81%) ($45.6000 - $45.6000) on Fri. Mar. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.39% (three month average) | RSI | 62 | Latest Price | $45.6000(-1.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(64%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.695% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-18%) UNG(-3%) IGOV(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.695% (StdDev 3.39%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
Resistance Level | $46.38 | 5 Day Moving Average | $47.23(-3.45%) | 10 Day Moving Average | $47.41(-3.82%) | 20 Day Moving Average | $46.38(-1.68%) | To recent high | -15.8% | To recent low | 9.4% | Market Cap | $5.775b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |